Search Results for 'Amgen Licenses DSM’s XD Cell Culture Patents'

Search For:
Refine by Dates:
From: To:
Refine By Content:

  • Too Much CMO Capacity?

    Eric A. Langer, BioPlan Associates || March 7, 2014
    A decade ago, there were dire concerns that the biopharmaceutical industry was headed for a severe crisis. There was, it was thought, inadequate mammalian manufacturing capacity to support the development pipeline. In particular, fears grew about sho…

  • Upstream Processes for Monoclonal Antibodies

    Upstream Processes for Monoclonal Antibodies

    Dominique Buteux, Aurore Lahille, Sebastien Ribault, Merck Millipore || September 5, 2013
    The importance of media selection and scale-down models for development

  • Amgen Licenses DSM’s XD Cell Culture Patents

    January 15, 2013
    Technology is applicable to multiple biological products

  • Bio-Growth Slowing?

    Bio-Growth Slowing?

    Eric Langer, BioPlan Associates || May 4, 2012
    A new report details bio-outsourcing trends in 2012

  • Biosimilar Outsourcing Update

    Gil Roth, Contract Pharma || May 4, 2012
    FDA’s draft guidance leads to new opportunities

  • Expression Technologies

    Expression Technologies

    Joel White, Ajinomoto North America || May 4, 2012
    To Outsource or License?

  • Excipients in Drug Delivery

    Excipients in Drug Delivery

    Balaji V. Kadri, Xcelience || June 6, 2011
    Trends in excipient selection for sustained release formulations

  • Contract Pharma Team

    Contract Pharma Team

    February 28, 2011
    .staffInfo {width:550px;float:left;} @media screen and (max-width: 600px){ .staffInfo {float:none;} } .staffPhoto {width:120px;float:left; padding-top:5px; padding-bottom:5px;} Contract Pharma Team President, Rodman J. Zil…

  • Takeda Chemical Industries

    Takeda Chemical Industries

    July 1, 2010
    #11 - Takeda Chemical Industries 1-1, Doshomachi 4-chome Chuo-ku Osaka 540-8645, Japan Tel: (81) 66 204 2111 Fax: (81) 66 204 2880 Headcount 19,654   Year Established 1781…